Citation: | WANG Dong, ZHONG Jian, WANG Ling, ZHOU Zhihui, JIANG Haiting, LUO Peng, WANG Xizhi, WANG Chongyi. Improved synthetic process of apremilast[J]. Journal of China Pharmaceutical University, 2021, 52(5): 536-540. DOI: 10.11665/j.issn.1000-5048.20210504 |
[1] |
. Guangzhou Chem Ind(广州化工),2015,43(10):107-108.
|
[2] |
Huang Q,Zhao SY. Synthesis of 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethenamine[J]. Biol Chem Eng(生物化工),2016,2(2):4-7.
|
[3] |
Lan XB,Zhu CS. Study on the synthesis of related substance of apremilast[J]. Guangdong Chem Ind(广东化工),2016,43(9):105-106.
|
[4] |
Liu FM. Improvement of synthesis processes of ramelteon,apremilast and chalcone(雷美替胺、阿普斯特及查耳酮合成工艺的改良)[D]. Wuxi:Jiangnan University,2015.
|
[5] |
SchaferP,MullerG,ManHW,et al. Preparing methods of(+)-2-[
1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]- 4 acetylaminoisoindoline 1, 3-dione and its compound((+)-2-[ 1-(3-乙氧基-4-甲氧基苯基)-2-甲磺酰基乙基]- 4-乙酰氨基异吲哚啉-1, CN1965823 B[P]. |
[6] |
Ruchelman AL,Connolly TJ. Enantioselective synthesis of the apremilast aminosulfone using catalytic asymmetric hydrogenation[J]. Tetrahedron Asymmetry,2015,26(10/11):553-559.
|
[7] |
Man HW,Schafer P,Wong LM,et al. Discovery of(S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide(apremilast),a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor[J]. J Med Chem,2009,52(6):1522-1524.
|
[8] |
Connolly TJ,Ruchelman AL,Yong KHY,et al. Processes for the preparation of isoindole compounds and isotopologues thereof:
US8981117[P]. |
[9] |
Strong M. FDA policy and regulation of stereoisomers:paradigm shift and the future of safer,more effective drugs[J]. Food Drug Law J,1999,54(3):463-487.
|
[10] |
Odingo JO. Inhibitors of PDE4:a review of recent patent literature[J]. Expert Opin Ther Patents,2005,15(7):773-787.
|
[11] |
Banner KH,Trevethick MA. PDE4 inhibition:a novel approach for the treatment of inflammatory bowel disease[J]. Trends Pharmacol Sci,2004,25(8):430-436.
|
[12] |
Jennifer RS,Duarte FJ,Stephanie AD. Oligomer-containing apremilast moiety compounds:
WO2012083153[P]. |
[13] |
Man HW,Schafer P,Wong LM,et al. Discovery of(S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide(apremilast),a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. J Med Chem,2009,52(6):1522-1524.
|
[14] |
Zhou JC. Applications of ammonium formate and other derivatives of formic acid in the drug synthesis[J]. J China Pharm Univ(中国药科大学学报),1989,20(5):313-320.
|
[15] |
Pharmaceuticals and Medical Devices Agency. Phosphodiesterase-4 inhibitors apremilast tablets(Otezla? tablets 10 mg 20 mg 30 mg)[EB/OL].
|
1. |
苏琦,张珂,黄淑琪,朱希强,刘晓鹏,姜宁. 逆境胁迫对药用植物药效成分积累的影响. 湖北民族大学学报(自然科学版). 2022(02): 129-134+180 .
![]() |